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Abstract
Background: In patients with ST-segment elevation myocardial infarction (STEMI) and 
multivessel disease (MVD), the treatment strategy for non-infarct-related artery (non-IRA) 
remains controversial. Quantitative flow ratio (QFR) is a new angiography-based 
physiological assessment index. However, there is little evidence on the practical clinical 
application of QFR. 
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Methods: Two hundred and twenty-nine patients with STEMI and MVD were recruited for 
this study. Patients were randomly assigned to either receive QFR-guided complete 
revascularization (QFR-G-CR) of non-IRA or receive no further invasive treatment. The 
primary (1º) endpoint analyzed included death due to all causes, non-fatal myocardial 
infarction (MI), and ischemia-induced revascularization at 12 months post-surgery. 
Secondary (2º) endpoints included cardiovascular death, unstable angina, stent thrombosis, 
New York Heart Association (NYHA) class IV heart failure (HF), and stroke at 1 year post 
surgery. Massive bleeding and contrast-associated acute kidney injury (CAKI) were used as 
safety endpoints.
Results: Around the 12 month follow up, the 1º outcome was recorded in 11/115 patients 
(9.6%) in the QFR-G-CR population, relative to 23/114 patients (20.1%) in the IRA-only PCI
population (hazard ratio [HR]: 0.45; 95% confidence interval [CI]: 0.22–0.92; p = 0.025). 
Unstable angina in 6 (5.2%) and 16 (14.0%) patients (HR: 0.36; 95% CI: 0.14–0.92; p = 
0.026), respectively. No marked alterations were found in the massive bleeding and CAKI 
categories.
Conclusions: In conclusion, STEMI and MVD patients can benefit from QFR-G-CR of non-
IRA lesions in the initial stages of acute MI. This can help reduce incidences of major adverse
cardiovascular events and unstable angina, relative to IRA treatment only. 
Chinese Clinical Trial Registration number: ChiCTR2100044120.
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Introduction
Multiple studies have revealed that 30–50% of patients with ST-elevation myocardial 
infarction (STEMI) exhibit additional severe stenotic lesions in the non-infarct-related artery 
(non-IRA) [1]. The recommended treatment for these patients is primary percutaneous 
coronary intervention (pPCI) for infarct-related artery (IRA) [2]. The importance of 
revascularization during pPCI for clinically important stenoses of non-IRA is controversial. 
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Prior studies have demonstrated that pPCI in non-IRA can be detrimental [3, 4]. Therefore, 
recent approaches are more geared toward complete revascularization (CR) [5–8]. However, 
the most suitable timing and program of PCI for these patients is still a common dilemma [9].
Earlier studies have revealed the highly beneficial use of Fractional flow reserve (FFR) 
guided PCI for positive long-term outcomes [10, 11]. Therefore, expanding the application of 
physiological assessment of lesions, a noninvasive, economical, and reliable tool to evaluate 
the functionality of non-IRA may be highly beneficial. The quantitative flow ratio (QFR) is 
an angiography-based procedure used to assess the extent of coronary stenosis, according to 
the three-dimensional quantitative coronary angiography (3D-QCA) and contrast frame 
counting. Recently, multiple studies have reported on the feasibility and accuracy of QFR in 
predicting stenosis [12–15]. In addition, trials have shown that QFR can also be used for the 
functional assessment of non-IRA in STEMI and multivessel disease (MVD) patients [16, 
17]. Our goal for this trial was to examine the efficacy of QFR-guided complete 
revascularization (CR) during the acute phase, relative to no invasive treatment, in STEMI 
and MVD patients, with previous pPCI of IRA.
Methods
Study design
This is a researcher-instigated, prospective, randomized clinical trial. Our goal was to 
evaluate the clinical outcomes of QFR-guided CR (QFR-G-CR) against IRA only 
revascularization in STEMI and MVD patients. Our hypothesis was that the QFR-G-CR 
procedure would reduce incidences of major adverse cardiovascular events (MACE) at 1 
year, relative to the IRA only revascularization procedure, with optimal medication treatment 
strategy. We followed the Declaration of Helsinki and were approved by the ethics committee
of the Affiliated Hospital of Hebei University (HDFY-KL-LL-2018-36). We also received 
informed agreement documents from all patients. Independent clinical research associates 
observed the trial and accumulated data.
Participants
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We recruited adult STEMI patients, who showed eligibility and were set up for pPCI 
within 12 hours of symptom onset. According to the contemporary guidelines, patients with 
STEMI > 12 hours of onset are also indicated for pPCI, if evidence of ischemia persists. All 
participates were hemodynamically stable after the pPCI procedure, and had ≥ 1 lesion, with 
a percent diameter stenosis (DS%) between 50% and 90% in ≥ 1 non-IRAs, with a > 2.0 mm 
standard vessel diameter by visual estimation or quantitative coronary angiography. 
Patients with any of the criteria listed below were excluded from the study: (1) severe 
heart failure (HF) or cardiogenic shock (New York Heart Association [NYHA] ≥ III); (2) 
strongly weakened kidney function: creatinine > 150 μmol/L or glomerular filtration rate 
(GFR) < 45 mL/kg/1.73 m2; (3) left main (LM) coronary artery disease; (4) chronic total 
occlusion (CTO); (5) allergic to contrast media or of relevant anticoagulants (unfraction 
heparin, bivalirudin and fondaparinux) or antiplatelet drugs (acetylsalicylic acid, clopidogrel 
and ticagrelor); (6) severe stenosis (DS% > 90%) with a TIMI flow grade ≤ 2 in the non-IRA;
(7) complications post IRA therapy; (8) severe valve dysregulation; (9) with prior coronary 
artery bypass grafting (CABG); and (10) any interrogated vessel regarded as not conducive to
QFR measurement. 
Randomization, treatment, and follow-up
Following a successful pPCI of IRA, we randomly assigned eligible patients to a QFR-
G-CR or an IRA-only revascularization cohort. Randomization was done by using a 
computer-processed random list. Please refer to Figure 1 for the randomized treatment and 
follow up examinations of patients. Given the risk of in-stent restenosis, drug-eluting stents 
(DES) were employed for all lesions. Patients, randomly picked for CR, underwent QFR 
measurements of non-IRA lesions. In case of all non-IRA lesions with QFR ≤ 0.80, PCI was 
conducted during patient’s hospital stays, regardless of the presence of clinical symptoms. 
However, patients with QFR > 0.80 in all examined vessels were not given PCI. Patients, in 
the IRA only revascularization patient population, received pPCI and no other invasive 
procedures. Optimal medical therapy, based on contemporary guidelines, was provided to 




QFR computation was done offline, with the AngioPlus system (Pulse Medical Imaging 
Technology, Shanghai, China), as per routine operational directions [12]. Two independent, 
certified operators performed the QFR computation. QFR ≤ 0.80 was used as the diagnostic 
cutoff value. We also performed QFR measurement after each surgery to analyze lesion 
correction. All angiogram files were stored in the core laboratory for further offline analysis.
Endpoints
The patients, in this study, were followed up till 1 year post surgery. The primary (1º) 
endpoint was the rate of MACE, which was a combination of patient death due to any reason,
nonfatal MI, and ischemia-induced revascularization for the QFR-G-CR versus IRA-only 
patient populations. Secondary (2º) endpoints included the cardiovascular death, unstable 
angina, stent thrombosis, NYHA class IV HF, and stroke. Massive bleeding (BARC ≥ type 3 
bleeding) [18] and contrast-associated acute kidney injury (CAKI) were used as safety 
endpoints. MI definition was the same as the fourth universal definition [19]. Ischemia-
induced revascularization represented any repeat pPCI or CABG, owing to constant chest 
pain, with or without electrocardiographic or biomarker alterations. Unstable angina was 
described as angina, even after appropriate therapy. Stent thrombosis was described as a stent 
site obstruction, in combination with acute myocardial ischemic manifestation, ischemic 
electrocardiographic alterations, or augmented myocardial enzymes levels. The definition of 
clinical events referred to the 2006 Academic Research Consortium (ARC) standards [24].
Statistical analysis
All outcomes from recruited patients were analyzed on an intent-to-treat approach. The 
1º outcomes were analyzed with the time-to-first-event approach. Categorical data, as clinical
event rates, are presented as numbers and percentages (%). Continuous data, evaluated with 
unpaired t-test, are presented as means ± standard deviations (SD) for evenly distributed 
variables and, assessed with Mann-Whitney U test, and presented as medians ± minimum 
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(min) and maximum (max) values for unevenly distributed variables. The Chi-square test or 
the Fisher exact test was employed for the assessment of categorical data. A two-sided p 
value < 0.05 was considered statistically significant. When evaluating the time-to-event 
endpoints, the log-rank test was used and the Kaplan-Meier technique was employed to 
depict survival probability. Cox proportional-hazard models were fitted to predict HRs (HR) 
with 95% confidence intervals (CI) for treatment comparisons. All analyses were performed 
with SPSS, version 22.0 (SPSS).
Results
Patients and baseline characteristics
Between August, 2019, and January, 2020, 229 STEMI and MVD patients who received 
pPCI were recruited for this study. The patients were randomized and 115 were placed in the 
QFR-G-CR category, and 114 in the IRA-only PCI category. The median follow-up time was 
12.5 months (interquartile range: 11.9–13.0). It was followed by all but 3 patients (2 in QFR-
G-CR and 1 in IRA-only PCI patient population) (Fig. 1). The baseline features and risk 
factors were relatively the same between the groups (Table 1).
Procedural data and treatment
Procedural information for both patient populations is listed in Table 2. The procedural 
time for the QFR-G-CR cohort, during PPCI, was ~14 minutes longer (p <0.001), with 37 mL
more of the contrast agent volume used (p < 0.001), relative to the IRA-only PCI cohort. The 
QFR-G-CR group used more stents per patient (p < 0.001) by treating more lesions. The 
proportion of MVD, use of radial access, and thrombus aspiration remained relatively the 
same in both cohorts (Table 2). The only exception was 1 participant of the IRA-only PCI 
cohort who received balloon dilation only. Both cohorts received the same management 
during discharge (Table 1).
QFR-related endpoints
In the QFR-G-CR group, QFR values were successfully measured in all lesions of non-
IRA (Table 2). The mean QFR value was 0.76 ± 0.11. Of the 115 patients allocated in this 
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group, 68 (59.1%) had QFR values for one or more lesions in non-IRA that were less than or 
equal to the discrimination value of 0.80. These lesions were chosen for stent placement (Fig.
2). In 42 (61.8%) of these 68 patients, additional PCI were performed during the pPCI 
procedure; the rest (26 patients, 38.2%) received early delayed PCI during the index 
admission (≤ 7 days). 
1º endpoints 
The 1o endpoint (MACE) was observed in 11 (9.6%) patients in the QFR-G-CR cohort, 
relative to 23 (20.1%) patients in the IRA-only PCI cohort at the 1-year follow-up (hazard 
ratio [HR]: 0.45; 95% CI: 0.22–0.92; p = 0.024) (Table 3, Fig. 3A). The Kaplan-Meier curves
diverged early, and remained separated at the 1-year follow-up (Fig. 3A). The 1o endpoint 
curves are presented in Figure 3B, C, D. The result was driven mainly by the higher incidence
of ischemia-driven revascularization performed in the latter group (7.2% vs. 16.7%; HR: 
0.40; 95% CI: 0.18–0.91; p = 0.024). Therefore, QFR-G-CR fared much better, compared to 
IRA-only revascularization, in that it produced a whopping 60% decrease in repeat 
revascularizations. 
2º and safety endpoints
Unstable angina event rate was observed in 6 (5.2%) patients in the QFR-G-CR cohort, 
relative to 16 (14.0%) patients in the IRA only PCI cohort (HR: 0.36; 95% CI: 0.14–0.92; p =
0.026) (Table 3, Fig. 4B). Other 2o endpoints in the two cohorts were not significantly 
different (Fig. 4A, C, D). Moreover, no significant difference was observed in massive 
bleeding and CAKI risk (Table 3).
Discussion
The present study demonstrated that supplementary QFR-G-CR of non-IRA lesions 
during or < 7 days post pPCI in STEMI and MVD patients produced a dramatically reduced 
rate of primary endpoint. This was primarily due to eliminating the need for repeat 
revascularizations. These findings are similar to other publications [6, 7]. Furthermore, in the 
2o endpoints, the incidence of unstable angina in the QFR-G-CR cohort was far less, 
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compared to the IRA-only cohort, suggesting that the QFR-G-CR procedure can greatly 
improve clinical outcomes and quality of life of patients. Although the volume of the contrast 
agent and the procedural time, during pPCI, in the QFR-G-CR cohort, were higher, as 
compared to the IRA-only cohort, no increase in other safety events, such as major bleeding 
or CAKI, was observed.
Previous studies demonstrated that non-IRA can be evaluated in STEMI with MVD 
patients during pPCI, but adenosine during the FFR process may cause slow blood flow and 
spasm in IRA. QFR, an angiography-based physiological assessment tool, presents an 
excellent option for the use of functional-based coronary stenosis examination, preventing the
risk and discomfort seen with pressure wires and adenosine [20]. Based on the results of this 
study, the QFR-G-CR group extended the operation time by an average of 14 minutes, which 
we believe is acceptable for STEMI patients with stable hemodynamics. However, there still 
exists a lack of evidence on the practical clinical application of QFR, and this study fills that 
gap. In the present trial, QFR-G-CR reduced MACE, and the percentage of angiographically 
significant non-IRA lesions with a 40% QFR > 0.80. This suggested that nearly half of the 
non-IRA lesions that coronary angiography considered significant were, in fact, not 
physiologically significant. 
There is still controversy regarding the optimal timing of early CR. Previous clinical 
trials, and recent meta-analyses, vary in the CR timing [21–23]. The CR with multi-vessel 
PCI for MI (COMPLETE) trial [8], with a larger sample size, demonstrated that CR fared 
much better than primary lesion only PCI, when performed within 45 days. In this trial, the 
QFR-G-CR for STEMI and MVD patients were performed during the acute phase of STEMI 
(during or within 7 days after pPCI). Based on our results, the composite outcome with good 
safety endpoints (no increase in major bleeding or CAKI) was only seen with the QFR-G-CR 
treatment strategy, but not with the IRA-only PCI
Limitations of the study
There were some limitations in this trial. This study could not meet blinding 
requirements, due to interventional treatment. Given the open-label design, there could be 
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bias that clinicians more likely performed subsequent revascularization on the IRA-only 
cohort. Some anatomic factors, such as ostial lesion, diffused long lesion, or severe vessel 
tortuosity, were not suitable for QFR assessment. Therefore, this can lead to selective bias 
among patients. As such, trials with larger patient populations are needed in future to discern 
the effects of QFR-G-CR on these endpoints. Finally, the present trial was followed-up for 1 
year, and to elucidate long-term outcomes, future trials with long-term follow-ups are needed.
Conclusions
In conclusion, among STEMI and MVD patients, the strategy of QFR-G-CR of non-IRA
lesions in the early stages of acute MI could reduce the incidence of MACE and unstable 
angina, relative to IRA treatment alone. Additionally, herein showed no increased risk of 
massive bleeding or CAKI within 1 year when using QFR-G-CR.
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Table 1. Patient demographic at baseline
Characteristic QFR-guided CR IRA-only PCI P
(n = 115) (n = 114)
Age [years] 62.1 ± 7.5 62.7 ± 6.2 0.54
Male 90 (78.2%) 91 (79.8%) 0.77
Hypertension 59 (51.3%) 60 (52.6%) 0.84
Diabetes 23 (20.0%) 21 (18.4%) 0.76
Hypercholesterolemia 38 (33.0%) 36 (31.2%) 0.81
Current smoker 56 (48.6%) 51 (44.7%) 0.55
Previous MI 9 (7.8%) 8 (7.0%) 0.82
Previous PCI 7 (6.1%) 6 (5.3%) 0.79
Previous stroke 6 (5.2%) 3 (2.6%) 0.51*
Location of infarct**
12
Anterior 39 (33.9%) 37 (32.5%) 0.82
Inferior 52 (45.2%) 55 (48.2%) 0.65
Posterior 18 (15.7%) 16 (14.0%) 0.73
Lateral 6 (5.2%) 6 (5.3%) 0.99
Symptom to balloon time [h]:
< 6 53 (46.1%) 51 (44.7%) 0.84
6 to 12 49 (42.6%) 47 (46.1%) 0.83
> 12 13 (11.3%) 16 (13.9%) 0.53
LDL-C [mmol/L] 3.0 ± 0.5 2.9 ± 0.4 0.16
Peak creatinine [μmol/L] 74.3 ± 13.7 76.3 ± 12.6 0.27
Medications at discharge:
Acetylsalicylic acid 115 (100%) 114 (100%)
P2Y12 inhibitors 115 (100%) 114 (100%)
Ticagrelor 82 (71.3%) 76 (66.7%) 0.45
Clopidogrel 33 (28.7%) 38 (33.3%)
Beta-blocker 107 (93.0%) 103 (90.4%) 0.46
ACEI or ARB 110 (95.7%) 108 (94.7%) 0.75
Statin 115 (100%) 114 (100%)
Data are shown as mean ± standard deviation or number (%). There were no significant differences between the 
two groups in any of the baseline characteristics.
*P values were calculated with the use of a continuity-corrected chi-square test.
**The location of the infarct was determined on the basis of electrocardiography.
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin-II-receptor blocker;  CR — complete 
revascularization; IRA= infarct-related artery; MI — myocardial infarction; LDL-C — low density lipoprotein 
cholesterol; PCI — percutaneous coronary intervention; QFR — quantitative flow ratio
Table 2. Procedural information.
Characteristic QFR-guided CR IRA-Only PCI P
(n = 115) (n = 114)
2-vessel disease 86 (74.8%) 83 (72.8%) 0.73
3-vessel disease 29 (25.2%) 31 (27.2%)
QFR-guided strategy:
QFR procedure successful in non-IRA: 115 (100%) NA
non-IRA Lesions with QFR ≤ 0.8 68 (59.1%) NA
non-IRA Lesions with QFR > 0.8 47 (40.9%) NA
Mean QFR value 0.76±0.11 NA
Non-IRA Lesions successfully treated 68/68 (100%) NA
During primary PCI procedure 42 (61.8%) NA
Early delayed (≤ 7d) 26 (38.2%) NA
Treatment method:
13
Drug-eluting stent 115 (100%) 113 (99.1%) 0.50*
Balloon dilation only 0 1 (0.9%)
No. of stents used per patient 2 (1–5) 1 (0–3) < 
0.001**
Procedure time during primary PCI [min] 63 (40–132) 49 (22–98) < 
0.001**
Volume of contrast agent used during 
primary PCI [mL]
195 (120–400) 158 (70–315) < 
0.001**
Radial access 109 (94.8%) 106 (93.0%) 0.57
Thrombus aspiration 38 (33.0%) 35 (30.7%) 0.70
Data are shown as mean ± standard deviation or number (%) or median (interquartile range).
*P values were calculated with the use of a Fisher’s exact test.
**P values were calculated with the use of a Mann-Whitney U test.
CR — complete revascularization; IRA — infarct-related artery; non-IRA — non-infarct-related artery; PCI — 
percutaneous coronary intervention; QFR — quantitative flow ratio





PCI (n = 
114)
Hazard ratio P 
(95% CI)
Primary endpoint
MACE (any first event)* 11 (9.6%) 23 (20.1%) 0.45 (0.22–0.92) 0.025
All-cause mortality 3 (2.6%) 4 (3.5%) 0.74 (0.17–3.30) 0.69
Nonfatal myocardial infarction 3 (2.6%) 5 (4.4%) 0.58 (0.14–2.44) 0.47
Ischemia-driven revascularization 8 (7.0%) 19 (16.7%) 0.40 (0.18–0.91) 0.024
PCI 8 (7.0%) 18 (15.8%) 0.42 (0.18–0.97) 0.037
Coronary artery bypass graft 0 1 (0.9%) NA NA
Secondary endpoints
Cardiovascular death 2 (1.7%) 2 (1.8%) 0.99 (0.14–7.01) 0.99
Unstable angina 6 (5.2%) 16 (14.0%) 0.36 (0.14–0.92) 0.026
Stent thrombosis 1 (0.9%) 1 (0.9%) 0.99 (0.06–15.78) 0.99
NYHA class IV heart failure 4 (3.5%) 5 (4.4%) 0.78 (0.21–2.91) 0.71
Stroke 0 1 (0.9%) NA NA
Safety endpoints
Major bleedings 3 (2.6%) 2 (1.8%) 1.48 (0.25–8.88) 0.66
Contrast-associated acute kidney injury 2 (1.7%) 1 (0.9%) 1.99 (0.18–21.93) 0.57
Values are number (%) for occurrences of both first events and total events.
*MACE denotes the composite of all-cause mortality, non-fatal myocardial infarction, and any ischemia-driven 
revascularization. 
CI — confidence interval; CR — complete revascularization; IRA — infarct-related artery; MACE — major 
adverse cardiovascular events; NYHA — New York Heart Association; PCI — percutaneous coronary 
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intervention; QFR — quantitative flow ratio
Figure 1. Enrollment, treatment, and follow-up. 229 patients with ST-segment elevation 
myocardial infarction (STEMI) and multivessel disease (MVD) were randomized to receive 
quantitative flow ratio (QFR)-guided complete revascularization (115) or infarct-related 
artery (IRA)-only percutaneous coronary intervention (PCI) (114). Patients were followed-up 
for 1 year, and analysis was by intention-to-treat. 
Figure 2. Example of quantitative flow ratio (QFR) computation in a right coronary artery 
(RCA). Example of assessment with QFR of a non-infarct-related artery (IRA) lesion; A, B. 
Non-IRA lesion in the mid-portion of RCA before percutaneous coronary intervention (PCI); 
C. Vessel QFR of RCA lesion before PCI; D, E. Non-IRA lesion in the mid-portion of RCA 
after PCI; F. Vessel QFR of RCA lesion after PCI. 
Figure 3. Kaplan-Meier Curves for the primary (1o) endpoint and its components; A. Kaplan-
Meier estimate of the survival rate of the 1o endpoint (major adverse cardiovascular events 
[MACE]); B–D. The components of MACE (all-cause mortality, nonfatal myocardial 
infarction, and ischemia-driven revascularization), respectively; CI — confidence interval; 
CR — complete revascularization; HR — hazard ratio; IRA — infarct-related artery; PCI — 
percutaneous coronary intervention; QFR — quantitative flow ratio.
Figure 4. Kaplan-Meier curves for the secondary (2o) endpoints; A–D. Kaplan-Meier 
estimates of the survival rate of the components of 2o endpoint (cardiovascular death, 
unstable angina, stent thrombosis, and New York Heart Association class IV heart failure), 
respectively; CI — confidence interval; CR — complete revascularization; HR — hazard 
ratio; IRA — infarct-related artery; PCI — percutaneous coronary intervention; QFR — 
quantitative flow ratio.
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